User Tag List

+ Reply to Thread
Page 1 of 2 12 LastLast
Results 1 to 10 of 15

Thread: Cancer breakthroughs, research & treatment

Hybrid View

  1. #1
    Points: 39,654, Level: 48
    Level completed: 69%, Points required for next Level: 496
    Overall activity: 0.1%
    Achievements:
    VeteranTagger First Class25000 Experience PointsSocial
    waltky's Avatar Senior Member
    Karma
    5662
    Join Date
    Oct 2012
    Posts
    8,859
    Points
    39,654
    Level
    48
    Thanks Given
    2,515
    Thanked 2,140x in 1,616 Posts
    Mentioned
    46 Post(s)
    Tagged
    0 Thread(s)

    Lightbulb Cancer breakthroughs, research & treatment

    Chemotherapy bath for liver cancer...

    First liver cancer 'chemo-bath' in the UK
    11 November 2012 : Chemotherapy affects the whole body and can cause side effects
    A "chemo-bath" which delivers toxic cancer drugs to just one organ in the body has been used on patients in the UK for the first time, say doctors. Chemotherapy drugs kill rapidly growing cells such as cancers, but they also attack healthy parts of the body. Doctors at Southampton General Hospital believe targeting just one organ can prevent side effects. They also say it means they can give higher doses without causing damage to the patient. Chemotherapy drugs are normally injected into the veins of patients. However, the whole body, rather than just the tumour, is exposed. It results in side effects such as fatigue, feeling sick, hair loss and damage to fertility.

    Targeted

    Two patients in the UK have now received chemotherapy focused on just their liver. Both had a rare eye cancer which had spread to the liver. The operation works by inflating balloons inside blood vessels on either side of the liver to isolate it from the rest of the body. The liver is then pumped full of chemotherapy drugs, which are filtered out before the liver is reconnected to the main blood supply. It means only a tiny fraction of the chemotherapy dose ends up in the body.

    Dr Brian Stedman, a consultant interventional radiologist, said: "To cut off an organ from the body for 60 minutes, soak it in a high dose of drug and then filter the blood almost completely clean before returning is truly groundbreaking. "Previously, the outlook for patients specifically suffering from cancer which has spread to the liver has been poor because standard chemotherapy's effect is limited by the unwanted damage the drug causes to the rest of the body." The surgery took place in the past three months and both patients are said to be doing well and their tumours "all look smaller", he said.

    Dr Stedman told the BBC: "In 20 years' time the idea of injecting a drug which poisons the whole body for a cancer in just one small area will seem bonkers." He suggested that any organ which could be easily separated from the blood supply, such as the kidney, pancreas and lungs, would be suitable for this kind of approach. However, he said the method was "in its infancy" and he was "not sure this is the finished product or the end of the story". The technique is also being tested in the US and elsewhere in Europe.

    http://www.bbc.co.uk/news/world-20270400

  2. #2
    Points: 62,451, Level: 61
    Level completed: 5%, Points required for next Level: 1,999
    Overall activity: 0.2%
    Achievements:
    SocialTagger First ClassVeteranRecommendation Second ClassOverdrive50000 Experience Points
    Calypso Jones's Avatar Banned
    Karma
    26181
    Join Date
    May 2012
    Location
    Shenandoah Valley, Virginia
    Posts
    14,239
    Points
    62,451
    Level
    61
    Thanks Given
    5,075
    Thanked 10,860x in 6,374 Posts
    Mentioned
    109 Post(s)
    Tagged
    0 Thread(s)
    Assuring that the Elites will ave their cures while the rest of us get our death panels.

  3. #3
    Points: 84,367, Level: 70
    Level completed: 80%, Points required for next Level: 483
    Overall activity: 3.0%
    Achievements:
    SocialVeteranTagger First Class50000 Experience Points
    roadmaster's Avatar Senior Member
    Karma
    10157
    Join Date
    Dec 2011
    Posts
    18,760
    Points
    84,367
    Level
    70
    Thanks Given
    3,287
    Thanked 6,300x in 4,607 Posts
    Mentioned
    143 Post(s)
    Tagged
    0 Thread(s)
    Quote Originally Posted by Calypso Jones View Post
    Assuring that the Elites will ave their cures while the rest of us get our death panels.
    I hope it doesn't happen in my lifetime but I do believe people will accept killing the ones in the nursing homes to reduce debt. They will see them as a burden on the health system.

  4. #4
    Points: 39,654, Level: 48
    Level completed: 69%, Points required for next Level: 496
    Overall activity: 0.1%
    Achievements:
    VeteranTagger First Class25000 Experience PointsSocial
    waltky's Avatar Senior Member
    Karma
    5662
    Join Date
    Oct 2012
    Posts
    8,859
    Points
    39,654
    Level
    48
    Thanks Given
    2,515
    Thanked 2,140x in 1,616 Posts
    Mentioned
    46 Post(s)
    Tagged
    0 Thread(s)

    Immuno-therapy drugs to fight cancer could be approved next year...

    Cancer cell therapies could be approved next year: Juno, Kite Pharma
    Sat Jun 4, 2016 - A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells could begin reaching patients next year, according to companies presenting new data at the annual meeting of the American Society of Clinical Oncology.
    In interviews with Reuters, Kite Pharma Inc (KITE.O) and Juno Therapeutics Inc (JUNO.O) both said they could receive initial regulatory approvals next year for a type of immunotherapy treatment known as chimeric antigen receptor T-cell (CAR-T) therapies. CAR-T therapies involve a complicated process of extracting immune system T cells from an individual patient, altering their DNA to sharpen their ability to spot and kill cancer cells, and infusing them back into the same patient. The technique is being tested against a range of different cancer types, but first in blood cancers. Kite aims to file this year for U.S. Food and Drug Administration approval of its therapy, KTE-C19, for patients with diffuse large B-cell lymphoma (DLBCL), according to Chief Medical Officer David Chang.

    Juno Chief Executive Officer Hans Bishop said adult patients with acute lymphoblastic leukemia (ALL) are now being enrolled in a mid-stage trial of the company's most advanced product, JCAR015, that "we believe will support accelerated approval." He said JCAR015 "could be approved as soon as 2017." Data presented on Saturday showed that 77 percent of patients with advanced ALL achieved a "complete response," meaning cancer remission, when treated with chemotherapy followed by Juno's cell therapy. For the trial patients with minimal disease, 90 percent achieved remission, researchers said. Twenty-seven percent of patients in the JCAR15 trial experienced a severe inflammatory response to the altered cells, and 15 percent had serious nervous system side effects.


    Preparations of media for cultivating cancer cells, being made in cancer research laboratories at the Old Road Campus research building at Oxford University, in Oxford, Britain

    Bishop said Juno has developed an assay to determine which patients are likely to experience risky side effects, but said the company has not yet disclosed the details. A separate National Institutes of Health early-stage study involving Kite's CAR-T drug and low-dose chemotherapy included 19 patients with various subtypes of DLBCL. Of those, eight patients achieved remission, five had partial responses, two had stable disease, and four had their cancer get worse. Two trial patients with advanced follicular lymphoma also obtained remissions. "In the near future, CAR-T cells will likely be a standard therapy for lymphoma," said lead study author James Kochenderfer, an investigator at the National Cancer Institute.

    Some patients treated with the still-experimental therapies have remained cancer free, but the jury is out on whether that will continue, or whether they will need new treatment. "Some of these responses are amazing in patients who would never have responded to anything," said ASCO President Dr Julie Vose. "The question is, is it practical? We are now seeing results for more patients, and longer follow up." Juno's Bishop said he is certain that the benefit of CAR-T therapies will be shown to outweigh any risks. "These are patients that are relapsed and refractory. They are going to die of their disease," he said. "We can get 90 to 100 percent of them into remission, and a meaningful percentage of them have durable remission."

    http://www.reuters.com/article/us-he...-idUSKCN0YQ0T1

  5. #5
    Points: 264,301, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 86.0%
    Achievements:
    50000 Experience PointsSocialVeteranTagger First ClassOverdrive
    Awards:
    Activity Award
    MisterVeritis's Avatar Senior Member
    Karma
    307871
    Join Date
    Oct 2014
    Location
    Northern Alabama
    Posts
    104,523
    Points
    264,301
    Level
    100
    Thanks Given
    94,656
    Thanked 39,245x in 27,866 Posts
    Mentioned
    385 Post(s)
    Tagged
    0 Thread(s)
    Quote Originally Posted by Calypso Jones View Post
    Assuring that the Elites will ave their cures while the rest of us get our death panels.
    LOL. In time, if it works, it will become the normal practice where it is appropriate.

  6. #6
    Points: 39,654, Level: 48
    Level completed: 69%, Points required for next Level: 496
    Overall activity: 0.1%
    Achievements:
    VeteranTagger First Class25000 Experience PointsSocial
    waltky's Avatar Senior Member
    Karma
    5662
    Join Date
    Oct 2012
    Posts
    8,859
    Points
    39,654
    Level
    48
    Thanks Given
    2,515
    Thanked 2,140x in 1,616 Posts
    Mentioned
    46 Post(s)
    Tagged
    0 Thread(s)

    Cool

    First-of-a-kind Test for Cancer Gene Profiling...


    FDA Approves First-of-a-kind Test for Cancer Gene Profiling
    December 01, 2017 - U.S. regulators have approved a first-of-a-kind test that looks for mutations in hundreds of cancer genes at once, giving a more complete picture of what's driving a patient's tumor and aiding efforts to match treatments to those flaws.
    The U.S. Food and Drug Administration approved Foundation Medicine's test for patients with advanced or widely spread cancers, and the Centers for Medicare and Medicaid Services proposed covering it. The dual decisions, announced late Thursday, will make tumor-gene profiling available to far more cancer patients than the few who get it now, and lead more insurers to cover it. "It's essentially individualized, precision medicine," said Dr. Kate Goodrich, chief medical officer for the Medicare oversight agency. Currently, patients may get tested for individual genes if a drug is available to target those mutations. It's a hit-and-miss approach that sometimes means multiple biopsies and wasted time. In lung cancer alone, for example, about half a dozen genes can be checked with individual tests to see if a particular drug is a good match.


    The new FoundationOne CDx test can be used for any solid tumor such as prostate, breast or colon cancer, and surveys 324 genes plus other features that can help predict success with treatments that enlist the immune system. "Instead of one or two, you have many" tests at once from a single tissue sample, said the FDA's Dr. Jeffrey Shuren. The tests give better and more information to guide treatment and can help more patients find and enroll in studies of novel therapies, he said. "This will be a sea change" for patients, said Dr. Richard Schilsky, chief medical officer of the American Society of Clinical Oncology, the association of doctors who treat the disease. "On balance I think this is good," but there is a risk that spotting a mutation will lead doctors and patients to try treatments that haven't been proven to work in that situation and promote more off-label use of expensive drugs, he said. A better outcome in those situations is to guide people into studies testing drugs that target those genes, Schilsky said.



    Patient Alison Cairnes (foreground) looks at images with her doctor Shumei Kato at the University of California San Diego in San Diego



    Foundation Medicine, based in Cambridge, Massachusetts, and others have sold tumor profiling tests for several years under more lax rules governing lab-developed tests. But insurers have balked at paying for the tests, which cost around $6,000. Now, the FDA's approval gives assurance of quality, Shuren said, and the government's proposed coverage for Medicare and other public insurance programs means private insurers will more likely follow. Public comments on the coverage proposal will be taken for 30 days. A final decision is expected early next year followed by setting a price for reimbursement. Coverage is proposed for patients with recurrent, widely spread or advanced cancers, in people who have decided with their doctors to seek further treatment and who have not previously had a gene sequencing test. "A lot of these folks have run out of treatment options," but the tests may point to something new that might help, Goodrich said. The impact is expected to be greatest on lung cancer, since so many of those tumors are found at an advanced stage and multiple gene-targeting drugs are available to treat it.


    Evidence isn't strong enough to warrant using these gene profiling tests for earlier stages of cancer. Patients get standard, guideline-based care in those cases. In mid-November, the FDA also approved a gene-profiling test developed by Memorial Sloan Kettering Cancer Center, but it's used almost exclusively on patients at that cancer center and is not envisioned to be a widely available commercial test. The federal decisions will make gene sequencing a more routine component of cancer care, "just like we normally look with a microscope" to classify the stage of a patient's disease, said Dr. David Klimstra, pathology chief at the cancer center. Another leader in this field, Caris Life Sciences, says it also intends to pursue FDA approval for its widely used tumor profiling test, sold now through lab certifications. It's also working on a newer tool to profile tumor genes from a blood sample. Many companies already sell these so-called liquid biopsy tests, though none are FDA-approved yet. This Associated Press series was produced in partnership with the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.


    https://www.voanews.com/a/fda-approv...g/4145522.html

  7. #7
    Points: 26,507, Level: 39
    Level completed: 66%, Points required for next Level: 443
    Overall activity: 2.0%
    Achievements:
    Recommendation Second ClassVeteranSocial50000 Experience Points
    Beevee's Avatar Senior Member
    Karma
    58827
    Join Date
    May 2012
    Location
    Near Montreal, Canada
    Posts
    8,818
    Points
    26,507
    Level
    39
    Thanks Given
    40
    Thanked 1,826x in 1,454 Posts
    Mentioned
    71 Post(s)
    Tagged
    0 Thread(s)
    Quote Originally Posted by Calypso Jones View Post
    Assuring that the Elites will ave their cures while the rest of us get our death panels.
    So can you put a figure on how many people in the US got 'their death panels' since the article was published four years ago?

  8. #8
    Original Ranter
    Points: 858,837, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 92.0%
    Achievements:
    SocialCreated Album picturesOverdrive50000 Experience PointsVeteran
    Awards:
    Posting Award
    Peter1469's Avatar Advisor
    Karma
    496507
    Join Date
    Jun 2011
    Location
    NOVA
    Posts
    241,624
    Points
    858,837
    Level
    100
    Thanks Given
    153,194
    Thanked 147,517x in 94,378 Posts
    Mentioned
    2552 Post(s)
    Tagged
    0 Thread(s)
    Quote Originally Posted by Beevee View Post
    So can you put a figure on how many people in the US got 'their death panels' since the article was published four years ago?
    Ask Paul (the DNC hack) Krugaman:

    ΜOΛΩΝ ΛΑΒΕ


  9. #9
    Points: 39,654, Level: 48
    Level completed: 69%, Points required for next Level: 496
    Overall activity: 0.1%
    Achievements:
    VeteranTagger First Class25000 Experience PointsSocial
    waltky's Avatar Senior Member
    Karma
    5662
    Join Date
    Oct 2012
    Posts
    8,859
    Points
    39,654
    Level
    48
    Thanks Given
    2,515
    Thanked 2,140x in 1,616 Posts
    Mentioned
    46 Post(s)
    Tagged
    0 Thread(s)

    DNA tweak 'boosts' cancer-killing cells...

    Gene editing 'boosts' cancer-killing cells
    Thu, 14 Apr 2016 - Cancer scientists have genetically modified the immune system to help them attack tumours in mice.
    Cancer scientists have genetically modified the immune system to help it attack tumours in mice. The immune system is the body's own defence against infection and cancer, but tumours develop ways of stopping the onslaught. The University College London team manipulated the DNA of immune cells to allow them to keep up the fight. Experts said the idea needed to be tested in human trials, but it was still exciting. Harnessing the power of the immune system to fight cancer is one of the most exciting fields in medicine. A lot of the research is targeted at the "chemical handshake" that tumours use to disable immune cells. A class of drugs called checkpoint inhibitors, such as pembrolizumab and nivolumab, interrupt the handshake and are already available for patients.


    This has lead to spectacular results for some patients, but it can lead to side-effects as the drugs affect the whole immune system. The approach now being tried effectively cuts off one of the hands - known technically as PD-1 - to prevent the handshake, but is targeted only at those immune cells attacking the cancer. In experiments on mice, scientists extracted killer T cells - which gobble up cancerous tissue - from inside the tumour. The assumption is the immune cells clustering inside the tumour are trained to attack it. Cutting edge gene editing technology was then used to change the DNA - the code of life - inside the killer T cells so that PD-1 was removed and cancers would be unable to stop them. It is known colloquially as "cutting the brakes". In experiments on melanoma and fibrosarcoma, mouse survival increased from less than 20% after 60 days without treatment to more than 70% with treatment.

    Dr Sergio Quezada, one of the researchers, said: "This is an exciting discovery and means we may have a way to get around cancer's defences while only targeting the immune cells that recognise the cancer. "While drugs that block PD-1 do show promise, this method only knocks out PD-1 on the T cells that can find the tumour - which could mean fewer side effects for patients." Dr Alan Worsley, from Cancer Research UK which funded the study, said: "I think it's actually pretty exciting - it's elegant, simple, straightforward and it makes sense. "We're going to see how this works in trials, but potentially it gets around the side effects." He said in immunotherapy drug trials "so many people had to come off because of the side effects, here it's not your whole immune system going crazy it's just those in the tumour."

    http://www.bbc.co.uk/news/health-36049907

  10. #10
    Points: 39,654, Level: 48
    Level completed: 69%, Points required for next Level: 496
    Overall activity: 0.1%
    Achievements:
    VeteranTagger First Class25000 Experience PointsSocial
    waltky's Avatar Senior Member
    Karma
    5662
    Join Date
    Oct 2012
    Posts
    8,859
    Points
    39,654
    Level
    48
    Thanks Given
    2,515
    Thanked 2,140x in 1,616 Posts
    Mentioned
    46 Post(s)
    Tagged
    0 Thread(s)

    Lightbulb

    New Biomarker to Guide Cancer Immunotherapy...
    Scientists Find New Biomarker to Guide Cancer Immunotherapy
    June 20, 2017 — Scientists said on Monday they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.
    The discovery, reported in the journal Nature Immunology, suggests doctors and drug developers will need to get smarter in zeroing in on those people who stand to benefit from the expensive new drugs, which are revolutionizing cancer care. Drugs such as Merck's Keytruda, Bristol-Myers Squibb's Opdivo, Roche's Tecentriq and AstraZeneca's Imfinzi can boost the immune system's ability to fight tumors, but they only work for some patients.

    The current widely used benchmark when giving cancer immunotherapy is a protein called PDL-1. However, many experts view PDL-1 as a "blunt instrument", since it does not match precisely to drug response, leading to the consideration of other measures, such as the level of mutation in tumors. The latest research adds a further twist by highlighting therole of so-called tissue-resident memory T-cells.

    A lymphoma patient receives cellular immunotherapy as part of a study at the Fred Hutchinson Cancer Research Center in Seattle, Washington.
    Researchers from the University of Southampton and La Jolla Institute for Allergy and Immunology found that lung cancer patients with lots of this cell type in their tumors were 34 percent less likely to die than others. "Having made the first baby steps with PDL-1 testing, we need to be smarter by using new tests," said Christian Ottensmeier, a Cancer Research UK scientist who worked on the study. "PDL-1 testing is a little bit like saying 'you've got a Ferrari because it is red.' Many Ferraris are red and many tumors that are PDL-1 positive will respond to immunotherapy, but on its own that is not sufficient."

    Ottensmeier and colleagues now plan further clinical trials to see how well their biological predictor can pick out patients who will benefit from taking Opdivo. Industry analysts expect the new generation of cancer immunotherapy drugs to generate tens of billions of dollars in annual sales by early next decade, with lung cancer the biggest single market.

    https://www.voanews.com/a/scientists...y/3907606.html
    See also:


    Living Drugs New Frontier for Cancer Patients Out of Options
    June 12, 2017 — Ken Shefveland's body was swollen with cancer, treatment after treatment failing until doctors gambled on a radical approach: They removed some of his immune cells, engineered them into cancer assassins and unleashed them into his bloodstream. Immune therapy is the hottest trend in cancer care and this is its next frontier - creating “living drugs” that grow inside the body into an army that seeks and destroys tumors.
    Looking in the mirror, Shefveland saw “the cancer was just melting away.” A month later doctors at the Fred Hutchinson Cancer Research Center couldn't find any signs of lymphoma in the Vancouver, Washington, man's body. “Today I find out I'm in full remission - how wonderful is that?” said Shefveland with a wide grin, giving his physician a quick embrace. This experimental therapy marks an entirely new way to treat cancer - if scientists can make it work, safely. Early-stage studies are stirring hope as one-time infusions of supercharged immune cells help a remarkable number of patients with intractable leukemia or lymphoma. “It shows the unbelievable power of your immune system,” said Dr. David Maloney, Fred Hutch's medical director for cellular immunotherapy who treated Shefveland with a type called CAR-T cells. “We're talking, really, patients who have no other options, and we're seeing tumors and leukemias disappear over weeks,” added immunotherapy scientific director Dr. Stanley Riddell. But, “there's still lots to learn.”



    A photo shows the cell processing facility at the Fred Hutchinson Cancer Research Center where workers create customized cellular immunotherapies for patients, in Seattle, Washington



    T cells are key immune system soldiers. But cancer can be hard for them to spot, and can put the brakes on an immune attack. Today's popular immunotherapy drugs called “checkpoint inhibitors” release one brake so nearby T cells can strike. The new cellular immunotherapy approach aims to be more potent: Give patients stronger T cells to begin with. Currently available only in studies at major cancer centers, the first CAR-T cell therapies for a few blood cancers could hit the market later this year. The Food and Drug Administration is evaluating one version developed by the University of Pennsylvania and licensed to Novartis, and another created by the National Cancer Institute and licensed to Kite Pharma. CAR-T therapy “feels very much like it's ready for prime time” for advanced blood cancers, said Dr. Nick Haining of the Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard, who isn't involved in the development.


    ‘There's a desperate need’


    Now scientists are tackling a tougher next step, what Haining calls “the acid test:” Making T cells target far more common cancers - solid tumors like lung, breast or brain cancer. Cancer kills about 600,000 Americans a year, including nearly 45,000 from leukemia and lymphoma. “There's a desperate need,” said NCI immunotherapy pioneer Dr. Steven Rosenberg, pointing to queries from hundreds of patients for studies that accept only a few. For all the excitement, there are formidable challenges. Scientists still are unraveling why these living cancer drugs work for some people and not others. Doctors must learn to manage potentially life-threatening side effects from an overstimulated immune system. Also concerning is a small number of deaths from brain swelling, an unexplained complication that forced another company, Juno Therapeutics, to halt development of one CAR-T in its pipeline; Kite recently reported a death, too. And, made from scratch for every patient using their own blood, this is one of the most customized therapies ever and could cost hundreds of thousands of dollars.


    MORE
    Last edited by waltky; 06-21-2017 at 03:31 AM.

+ Reply to Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts